Galapagos Genomics

From Wikipedia, the free encyclopedia

Galapagos Genomics NV is a biotech company located in Mechelen, Belgium. The company was founded in 1999 as a joint venture between Crucell (formerly IntroGene) and Tibotec. The company has its own internal discovery programs which it combines with drug discovery and pre-clinical service activities for other biotech and pharmaceutical companies.

The company uses a technological platform for its research, which is based on adenoviruses to introduce human gene sequences into a wide variety of human cell lines to knock-in or knock-down specific proteins.

[edit] References

  • Edwards PJ., The impact of parallel chemistry in drug discovery, IDrugs. 2006 May;9(5):347-53.

[edit] See also

[edit] External links


  This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.
Retrieved from "http://en.wikipedia.org../../../g/a/l/Galapagos_Genomics_5a48.html"